Skip to main
RGNX

REGENXBIO (RGNX) Stock Forecast & Price Target

REGENXBIO (RGNX) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 44%
Buy 44%
Hold 11%
Sell 0%
Strong Sell 0%

Bulls say

Regenxbio is in a strong financial position, and the potential risks associated with their gene therapy treatments such as potential equity dilution and a theoretical risk of tumorigenesis are being carefully monitored and investigated. The recent discovery of a tumor in a pediatric patient receiving their AAV-based therapy has not been conclusively linked to the treatment, and the patient has recovered without any negative effects. The company has a promising pipeline and is showing positive developmental advancements in their ongoing clinical trials.

Bears say

Regenxbio is a clinical-stage biotechnology company focused on developing gene therapy treatments for genetic defects and diseases using their NAV Technology Platform. However, numerous factors contribute to our negative outlook on the company, including uncertainties surrounding their product candidates, declining financials, patent expirations, potential competition, and manufacturing risks. These factors make us cautious about the company's future prospects and potential for success, leading us to have a negative outlook on the stock.

REGENXBIO (RGNX) has been analyzed by 9 analysts, with a consensus rating of Buy. 44% of analysts recommend a Strong Buy, 44% recommend Buy, 11% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of REGENXBIO and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About REGENXBIO (RGNX) Forecast

Analysts have given REGENXBIO (RGNX) a Buy based on their latest research and market trends.

According to 9 analysts, REGENXBIO (RGNX) has a Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $24.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $24.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

REGENXBIO (RGNX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.